Pharmacotherapy of the overactive bladder.

Area of Science:

• Urology
• Pharmacology
• Neuroscience

Background:

• Lower urinary tract symptoms (LUTS), overactive bladder (OAB), and detrusor overactivity (DO) significantly impair quality of life.
• Current first-line antimuscarinic treatments for LUTS/OAB/DO face challenges with adverse effects and long-term compliance.
• Understanding urothelial function, myocyte activity, and neurotransmitter roles opens new therapeutic avenues.

Purpose of the Study:

• To review emerging therapeutic strategies for LUTS/OAB/DO beyond traditional antimuscarinics.
• To explore novel drug targets and mechanisms for managing bladder dysfunction.
• To assess the potential of new treatments based on recent clinical trial evidence.

Main Methods:

• Review of randomized controlled trials evaluating novel pharmacological agents.
• Analysis of drugs targeting peripheral and central mechanisms of bladder control.
• Inclusion of agents like beta3-adrenoceptor agonists, PDE5 inhibitors, and centrally acting drugs.

Main Results:

• Beta3-adrenoceptor agonists (e.g., mirabegron) demonstrate proof of concept.
• Phosphodiesterase type 5 inhibitors (e.g., sildenafil, tadalafil) show efficacy.
• Combinational therapies and centrally acting agents (e.g., tramadol, gabapentin) also present positive trial data.

Conclusions:

• Several novel therapeutic principles show promise for treating LUTS/OAB/DO.
• These include beta3-AR agonists, PDE5 inhibitors, combination therapies, and centrally acting drugs.
• Further development is required to establish which of these will become clinically useful treatments.